دورية أكاديمية
أعرض في EDS

Novel Immunosuppression in Solid Organ Transplantation.

التفاصيل البيبلوغرافية
العنوان: Novel Immunosuppression in Solid Organ Transplantation.
المؤلفون: Konda P; Heart and Vascular Institute, Pennsylvania State University/Milton S. Hershey Medical Center, Hershey, PA, USA., Golamari R; Department of Hospital Medicine, Pennsylvania State University/Milton S. Hershey Medical Center, Hershey, PA, USA., Eisen HJ; Heart and Vascular Institute, Pennsylvania State University/Milton S. Hershey Medical Center, Hershey, PA, USA. heisen@pennstatehealth.psu.edu.
المصدر: Handbook of experimental pharmacology [Handb Exp Pharmacol] 2022; Vol. 272, pp. 267-285.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902231 Publication Model: Print Cited Medium: Print ISSN: 0171-2004 (Print) Linking ISSN: 01712004 NLM ISO Abbreviation: Handb Exp Pharmacol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin, New York, Springer-Verlag.
مواضيع طبية MeSH: Graft Rejection*/prevention & control , Organ Transplantation*/adverse effects, Calcineurin Inhibitors/therapeutic use ; Humans ; Immunosuppression Therapy ; Immunosuppressive Agents/adverse effects ; Steroids
مستخلص: Solid organ transplantation and survival has improved tremendously in the last few decades, much of the success has been attributed to the advancements in immunosuppression. While steroids are being replaced and much of the immunosuppressive strategies focus on steroid free regimens, novel agents have introduced in the induction, maintenance, and treatment of acute rejection phase. MTOR inhibitors have helped with the renal sparing side effect from the calcineurin inhibitors, newer agents such as rituximab have decreased the incidence of donor-specific antibodies which led to decreased incidence of acute rejection reactions. In this chapter we discuss the newer therapies directed specifically for solid organ transplantation.
(© 2022. Springer Nature Switzerland AG.)
References: Aguero J, Almenar L, Martínez-Dolz L, Moro JA, Rueda J, Raso R et al (2008) Influence of immunosuppressive regimens on short-term morbidity and mortality in heart transplantation. Clin Transpl 22(1):98–106. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1399-0012.2007.00751.x.
Alishetti S, Farr M, Jennings D, Serban G, Uriel N, Sayer G et al (2020) Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. Am J Transplant 20(12):3620–3630. (PMID: 32506824836674610.1111/ajt.16113)
Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E et al (2014) Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant 14(8):1828–1838. (PMID: 2504122710.1111/ajt.12809)
Andreassen AK, Broch K, Eiskjær H, Karason K, Gude E, Mølbak D et al (2019) Blood pressure in de novo heart transplant recipients treated with everolimus compared with a cyclosporine-based regimen: results from the randomized SCHEDULE trial. Transplantation 103(4):781–788. (PMID: 3021182610.1097/TP.0000000000002445)
Anne K, Meroula R, Peter R, Phillip S, Andrew G, Gerry O’D et al (2004) Sirolimus in De Novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. Circulation 110(17):2694–2700. https://www.ahajournals.org/doi/10.1161/01.CIR.0000136812.90177.94. (PMID: 10.1161/01.CIR.0000136812.90177.94)
Ansari D, Höglund P, Andersson B, Nilsson J (2015a) Comparison of basiliximab and anti-thymocyte globulin as induction therapy in Pediatric heart transplantation: a survival analysis. J Am Heart Assoc 5(1):e002790. (PMID: 26722127485939810.1161/JAHA.115.002790)
Ansari D, Lund LH, Stehlik J, Andersson B, Höglund P, Edwards L et al (2015b) Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab. J Heart Lung Transplant 34(10):1283–1291. (PMID: 2608766710.1016/j.healun.2015.04.001)
Aranda JM, Scornik JC, Normann SJ, Lottenberg R, Schofield RS, Pauly DF et al (2002) Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 73(6):907–910. (PMID: 1192369010.1097/00007890-200203270-00013)
Arora S, Gude E, Sigurdardottir V, Mortensen SA, Eiskjær H, Riise G et al (2012) Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate. J Heart Lung Transplant 31(3):259–265. https://www.jhltonline.org/article/S1053-2498(11)01259-9/abstract. (PMID: 2233340310.1016/j.healun.2011.12.010)
Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Bøtker HE et al (2015) The effect of Everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in De novo recipients: one-year results of a Scandinavian randomized trial. Am J Transplant 15(7):1967–1975. (PMID: 2578397410.1111/ajt.13214)
Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskjær H, Bøtker HE et al (2018) Effect of Everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in De Novo heart transplant recipients. Circ Heart Fail 11(9):e004050. (PMID: 3035436210.1161/CIRCHEARTFAILURE.117.004050)
Ballow M (2011) The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 127(2):315–23; quiz 324–5. (PMID: 2118507110.1016/j.jaci.2010.10.030)
Baran DA, Lubitz S, Alvi S, Fallon JT, Kaplan S, Galin I et al (2004) Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Transplant Proc 36(10):3164–3166. (PMID: 1568671910.1016/j.transproceed.2004.10.087)
Barnard CN (1967) The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. South Afr Med J Suid-Afr Tydskr Vir Geneeskd 41(48):1271–1274.
Bennett WM (1996) Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 34(11):515–519. (PMID: 8937936)
Bourassa-Blanchette S, Patel V, Knoll GA, Hutton B, Fergusson N, Bennett A et al (2019) Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: a systematic review and meta-analysis – part II: non-kidney transplant. Clin Transpl 33(7):e13625. http://onlinelibrary.wiley.com/doi/abs/10.1111/ctr.13625. (PMID: 10.1111/ctr.13625)
Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM et al (2006) Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17(2):581–589. https://jasn.asnjournals.org/content/17/2/581. (PMID: 1643450610.1681/ASN.2005090993)
Carlsen J, Johansen M, Boesgaard S, Andersen CB, Arendrup H, Aldershvilet J et al (2005) Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. J Heart Lung Transplant 24(3):296–302. https://www.jhltonline.org/article/S1053-2498(04)00088-9/abstract. (PMID: 1573775610.1016/j.healun.2003.12.014)
Chen J, Wang Q, Yin D, Vu V, Sciammas R, Chong AS (2015) Cutting edge: CTLA-4Ig inhibits memory B cell responses and promotes allograft survival in sensitized recipients. J Immunol 195(9):4069–4073. (PMID: 2641627010.4049/jimmunol.1500940)
Chin C, Pittson S, Luikart H, Bernstein D, Robbins R, Reitz B et al (2005) Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation 80(4):477–481. (PMID: 1612372110.1097/01.tp.0000168153.50774.30)
Chivukula S, Shullo MA, Kormos RL, Bermudez CA, McNamara DM, Teuteberg JJ (2014) Cancer-free survival following alemtuzumab induction in heart transplantation. Transplant Proc 46(5):1481–1488. (PMID: 2493531710.1016/j.transproceed.2014.04.001)
Chou NK, Wang SS, Chen YS, Yu HY, Chi NH, Wang CH et al (2008) Induction immunosuppression with basiliximab in heart transplantation. Transplant Proc 40(8):2623–2625. (PMID: 1892982010.1016/j.transproceed.2008.07.113)
Collins WA, Humphreys RM, Davis MB, Ibele WE, Dworkin M, Kinsey J et al (1996) The crime of saving lives: the FDA, John Najarian, and Minnesota ALG. Arch Surg 131(4):451–452. (PMID: 861573610.1001/archsurg.1996.01430160109024)
Costanzo MR (2001) New immunosuppressive drugs in heart transplantation. Curr Control Trials Cardiovasc Med 2(1):45–53. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59653/. (PMID: 118067725965310.1186/CVM-2-1-045)
Coutance G, Ouldamar S, Rouvier P, Saheb S, Suberbielle C, Bréchot N et al (2015) Late antibody-mediated rejection after heart transplantation: mortality, graft function, and fulminant cardiac allograft vasculopathy. J Heart Lung Transplant 34(8):1050–1057. (PMID: 2595674010.1016/j.healun.2015.03.002)
Cuppoletti A, Perez-Villa F, Vallejos I, Roig E (2005) Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation. Transplant Proc 37(9):4036–4038. (PMID: 1638662010.1016/j.transproceed.2005.10.086)
Delgado DH, Miriuka SG, Cusimano RJ, Feindel C, Rao V, Ross HJ (2005) Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant 24(2):166–169. (PMID: 1570143210.1016/j.healun.2003.09.043)
Delgado JF, Vaqueriza D, Sánchez V, Escribano P, Ruiz-Cano MJ, Renes E et al (2011) Induction treatment with monoclonal antibodies for heart transplantation. Transplant Rev 25(1):21–26. http://www.sciencedirect.com/science/article/pii/S0955470X10000728. (PMID: 10.1016/j.trre.2010.10.002)
Donna M, Sean P, Daniel B, John LM, Silviu I, Elizabeth B et al (2003) Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108(1):48–53. https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000070421.38604.2B. (PMID: 10.1161/01.CIR.0000070421.38604.2B)
Edwards JJ, Seliktar N, White R, Heron SD, Lin K, Rossano J et al (2019) Impact and predictors of positive response to desensitization in Pediatric heart transplant candidates. J Heart Lung Transplant 38(11):1206–1213. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827717/. (PMID: 31672220682771710.1016/j.healun.2019.08.018)
Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA et al (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349(9):847–858. https://doi.org/10.1056/NEJMoa022171. (PMID: 10.1056/NEJMoa02217112944570)
Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H et al (2013) Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 13(5):1203–1216. https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.12181. (PMID: 2343310110.1111/ajt.12181)
Enderby CY, Habib P, Patel PC, Yip DS, Orum S, Hosenpud JD (2014) Belatacept maintenance in a heart transplant recipient. Transplantation 98(7):e74. https://journals.lww.com/transplantjournal/Fulltext/2014/10150/Belatacept_Maintenance_in_a_Heart_Transplant.21.aspx. (PMID: 2528595610.1097/TP.0000000000000404)
Engelen MA, Amler S, Welp H, Vahlhaus C, Gunia S, Sindermann JR et al (2011) Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years. Transplantation 91(10):1159–1165. (PMID: 2147881710.1097/TP.0b013e31821774bd)
Eugenia R, Jang-Ho B, Zain K, Edwards BS, Kremers WK, Clavell AL et al (2007) Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 116(23):2726–2733. https://www.ahajournals.org/doi/10.1161/circulationaha.107.692996. (PMID: 10.1161/CIRCULATIONAHA.107.692996)
Everly MJ, Terasaki PI, Trivedi HL (2012) Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation 93(6):572–577. https://journals.lww.com/transplantjournal/Fulltext/2012/03270/Durability_of_Antibody_Removal_Following.2.aspx. (PMID: 2226212810.1097/TP.0b013e31824612df)
Fernandez Rivera C, Alonso Hernandez A, Villaverde Verdejo P, Oliver García J, Valdés Cañedo F (2005) Basiliximab (Simulect) in renal transplantation with high risk for delayed graft function. Transplant Proc 37(3):1435–1437. (PMID: 1586662910.1016/j.transproceed.2005.02.007)
Gale SE, Ravichandran B, Ton V-K, Pham S, Reed BN (2019) Alemtuzumab induction versus conventional immunosuppression in heart transplant recipients. J Cardiovasc Pharmacol Ther 24(5):435–441. (PMID: 3103577710.1177/1074248419841635)
Garrett HE, Duvall-Seaman D, Helsley B, Groshart K (2005) Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant 24(9):1337–1342. (PMID: 1614325410.1016/j.healun.2004.09.003)
Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2):128–135. (PMID: 1182189610.1038/nm0202-128)
Guethoff S, Stroeh K, Grinninger C, Koenig MA, Kleinert EC, Rieger A et al (2015) De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results. J Heart Lung Transplant 34(5):634–642. (PMID: 2570137310.1016/j.healun.2014.11.025)
Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E et al (2020) Everolimus initiation with early calcineurin inhibitor withdrawal in De novo heart transplant recipients: long-term follow-up from the randomized SCHEDULE study. Transplantation 104(1):154–164. https://journals.lww.com/transplantjournal/Fulltext/2020/01000/Everolimus_Initiation_With_Early_Calcineurin.31.aspx. (PMID: 3089329210.1097/TP.0000000000002702)
Hershberger RE, Starling RC, Eisen HJ, Bergh C-H, Kormos RL, Love RB et al (2009) Daclizumab to prevent rejection after cardiac transplantation. Massachusetts Medical Society. https://www.nejm.org/doi/10.1056/NEJMoa032953.
Higgins R, Kirklin JK, Brown RN, Rayburn BK, Wagoner L, Oren R et al (2005) To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? J Heart Lung Transplant 24(4):392–400. https://www.sciencedirect.com/science/article/pii/S1053249804000348. (PMID: 1579773810.1016/j.healun.2004.01.002)
Jennings DL, Lange N, Shullo M, Latif F, Restaino S, Topkara VK et al (2018) Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: a meta-analysis. Int J Cardiol 265:71–76. https://www.internationaljournalofcardiology.com/article/S0167-5273(18)31103-3/abstract. (PMID: 2960547010.1016/j.ijcard.2018.03.111)
John R, Lietz K, Burke E, Ankersmit J, Mancini D, Suciu-Foca N et al (1999) Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 100(19 Suppl):II229–II235. (PMID: 10567309)
Khuu T, Cadeiras M, Wisniewski N, Reed EF, Deng MC (2015) Reduced HLA class II antibody response to proteasome inhibition in heart transplantation. J Heart Lung Transplant 34(6):863–865. https://www.sciencedirect.com/science/article/pii/S105324981501030X. (PMID: 2581696910.1016/j.healun.2015.01.982)
Kittipibul V, Tantrachoti P, Ongcharit P, Ariyachaipanich A, Siwamogsatham S, Sritangsirikul S et al (2017) Low-dose basiliximab induction therapy in heart transplantation. Clin Transpl 31(12). https://doi.org/10.1111/ctr.13132.
Kobashigawa J, David K, Morris J, Chu AH, Steffen BJ, Gotz VP et al (2005) Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant Proc 37(2):1333–1339. (PMID: 1584871310.1016/j.transproceed.2004.12.135)
Kobashigawa JA, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK, Davis SN et al (2011) The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin Transpl 25(1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829691/.
Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang S-S et al (2013a) Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial. JACC Heart Fail 1(5):389–399. (PMID: 2462197110.1016/j.jchf.2013.07.002)
Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB et al (2013b) Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl Infect Dis 15(2):150–162. (PMID: 2301344010.1111/tid.12007)
Kumar D, Yakubu I, Cooke RH, Halloran PF, Gupta G (2018) Belatacept rescue for delayed kidney allograft function in a patient with previous combined heart-liver transplant. Am J Transplant 18(10):2613–2614. https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.15003. (PMID: 2998118410.1111/ajt.15003)
Kushwaha SS, Raichlin E, Sheinin Y, Kremers WK, Chandrasekaran K, Brunn GJ et al (2008) Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. Eur Heart J 29(22):2742–2750. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721707/. (PMID: 18790727272170710.1093/eurheartj/ehn407)
Launay M, Guitard J, Dorent R, Prevot Y, Prion F, Beaumont L et al (2020) Belatacept-based immunosuppression: a calcineurin inhibitor-sparing regimen in heart transplant recipients. Am J Transplant 20(2):553–563. (PMID: 3145233710.1111/ajt.15584)
Lehmkuhl HB, Arizon J, Viganò M, Almenar L, Gerosa G, Maccherini M et al (2009) Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 88(1):115–122. (PMID: 1958469010.1097/TP.0b013e3181aacd22)
Li KHC, Ho JCS, Recaldin B, Gong M, Ho J, Li G et al (2018) Acute cellular rejection and infection rates in alemtuzumab vs traditional induction therapy agents for lung and heart transplantation: a systematic review and meta-analysis. Transplant Proc 50(10):3723–3731. (PMID: 3057726310.1016/j.transproceed.2018.08.044)
Lick SD, Vaidya S, Kollar AC, Boor PJ, Vertrees RA (2008) Peri-operative alemtuzumab (Campath-1H) and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular assist device support. J Heart Lung Transplant 27(9):1036–1039. (PMID: 1876519810.1016/j.healun.2008.06.004)
López-Vilella R, Sánchez-Lázaro IJ, Martínez-Dolz L, Almenar-Bonet L, Marqués-Sulé E, Melero-Ferrer J et al (2015) Incidence of development of obesity after heart transplantation according to the calcineurin inhibitor. Transplant Proc 47(1):127–129. https://www.sciencedirect.com/science/article/pii/S0041134514012779. (PMID: 2564578910.1016/j.transproceed.2014.11.025)
Ludwig B, Schneider J, Föll D, Zhou Q (2020) Antibody-mediated rejection with detection of de novo donor-specific anti-human leucocyte antigen class II antibodies 3 years after heart transplantation: a case report. Eur Heart J Case Rep 4(1):1–4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047055/. (PMID: 32128488704705510.1093/ehjcr/ytz246)
Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI et al (2014) The Registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report—2014; focus theme: retransplantation. J Heart Lung Transplant 33(10):996–1008. http://www.sciencedirect.com/science/article/pii/S1053249814012601. (PMID: 2524212410.1016/j.healun.2014.08.003)
Mahmud N, Klipa D, Ahsan N (2010) Antibody immunosuppressive therapy in solid-organ transplant. MAbs 2(2):148–156. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840233/. (PMID: 20150766284023310.4161/mabs.2.2.11159)
Martin ST, Powell JT, Patel M, Tsapepas D (2013) Risk of posttransplant lymphoproliferative disorder associated with use of belatacept. Am J Health-Syst Pharm 70(22):1977–1983. (PMID: 2417300710.2146/ajhp120770)
Martin ST, Kato TS, Farr M, McKeen JT, Cheema F, Ji M et al (2015) Similar survival in patients following heart transplantation receiving induction therapy using daclizumab vs. basiliximab. Circ J 79(2):368–374. (PMID: 2550195110.1253/circj.CJ-14-0718)
Mattei MF, Redonnet M, Gandjbakhch I, Bandini AM, Billes A, Epailly E et al (2007) Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 26(7):693–699. (PMID: 1761339910.1016/j.healun.2007.05.002)
Mudge Gilbert H (2007) Sirolimus and cardiac transplantation. Circulation 116(23):2666–2668. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.737965. (PMID: 1805653810.1161/CIRCULATIONAHA.107.737965)
Mueller XM (2004) Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants. Ann Thorac Surg 77(1):354–362. http://www.sciencedirect.com/science/article/pii/S0003497503017879. (PMID: 1472610410.1016/j.athoracsur.2003.07.006)
Mullen JC, Kuurstra EJ, Oreopoulos A, Bentley MJ, Wang S (2014) A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation. Transplant Res 3(1):14. https://doi.org/10.1186/2047-1440-3-14. (PMID: 10.1186/2047-1440-3-14250930774120716)
Nozohoor S, Stehlik J, Lund LH, Ansari D, Andersson B, Nilsson J (2020) Induction immunosuppression strategies and long-term outcomes after heart transplantation. Clin Transpl 34(7):e13871. (PMID: 10.1111/ctr.13871)
Ortiz V, Almenar L, Martínez-Dolz L, Zorio E, Chamorro C, Moro J et al (2006) Induction therapy with daclizumab in heart transplantation--how many doses? Transplant Proc 38(8):2541–2543. (PMID: 1709799510.1016/j.transproceed.2006.08.024)
Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J (2011) Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J Heart Lung Transplant 30(12):1320–1326. https://www.jhltonline.org/article/S1053-2498(11)01110-7/abstract. (PMID: 2196813010.1016/j.healun.2011.08.009)
Patel J, Reinsmoen N, Kittleson M, Dilibero D, Liou F, Chang DH et al (2015a) Plasmapheresis and bortezomib for sensitized patients awaiting heart transplantation - worth the effort? J Heart Lung Transplant 34(4):S30–S31. https://www.jhltonline.org/article/S1053-2498(15)00099-6/abstract. (PMID: 10.1016/j.healun.2015.01.072)
Patel J, Dilibero D, Kittleson M, Sana S, Liou F, Chang DH et al (2015b) Terminal complement inhibition for highly sensitized patients undergoing heart transplantation - doable? J Heart Lung Transplant 34(4):S31. https://linkinghub.elsevier.com/retrieve/pii/S105324981500100X. (PMID: 10.1016/j.healun.2015.01.073)
Patel JK, Coutance G, Loupy A, Dilibero D, Hamilton M, Kittleson M et al (2021) Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. Am J Transplant. https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.16420.
Penninga L, Møller CH, Gustafsson F, Steinbrüchel DA, Gluud C (2010) Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol 66(12):1177–1187. (PMID: 2088227310.1007/s00228-010-0902-6)
Petrakopoulou P, Anthopoulou L, Muscholl M, Klauss V, von Scheidt W, Überfuhr P et al (2006) Coronary endothelial vasomotor function and vascular Remodeling in heart transplant recipients randomized for tacrolimus or cyclosporine immunosuppression. J Am Coll Cardiol 47(8):1622–1629. https://www.sciencedirect.com/science/article/pii/S0735109706001690. (PMID: 1663100010.1016/j.jacc.2005.10.073)
Petrikovits E, Bedanova H, Necas J, Studenik P, Cerny J (2005) Daclizumab in the induction phase of immunosuppression in heart transplant recipients. Ann Transplant 10(3):5–10. https://www.annalsoftransplantation.com/download/index/idArt/433648. (PMID: 16617659)
Potena L, Prestinenzi P, Bianchi IG, Masetti M, Romani P, Magnani G et al (2012) Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study. J Heart Lung Transplant 31(6):565–570. https://www.jhltonline.org/article/S1053-2498(12)00014-9/abstract. (PMID: 2234170210.1016/j.healun.2012.01.002)
Potena L, Pellegrini C, Grigioni F, Amarelli C, Livi U, Maccherini M et al (2018) Optimizing the safety profile of Everolimus by delayed initiation in De Novo heart transplant recipients: results of the prospective randomized study EVERHEART. Transplantation 102(3):493–501. (PMID: 28930797582837510.1097/TP.0000000000001945)
Rabea A, Alexandros B, Kremers WK, Rosalyn A, Boilson BA, Pereira NL et al (2018) Long-term sirolimus for primary immunosuppression in heart transplant recipients. J Am Coll Cardiol 71(6):636–650. https://www.jacc.org/doi/full/10.1016/j.jacc.2017.12.005. (PMID: 10.1016/j.jacc.2017.12.005)
Ravichandran AK, Schilling JD, Novak E, Pfeifer J, Ewald GA, Joseph SM (2013) Rituximab is associated with improved survival in cardiac allograft patients with antibody-mediated rejection: a single center review. Clin Transpl 27(6):961–967. (PMID: 10.1111/ctr.12277)
Sacha L, Teuteberg JJ, Zeevi A, Bermudez C, Kormos R, Ensor C et al (2014) Carfilzomib for refractory antibody mediated rejection and allosensitization in heart transplantation. J Heart Lung Transplant 33(4):S31. https://www.jhltonline.org/article/S1053-2498(14)00126-0/abstract. (PMID: 10.1016/j.healun.2014.01.112)
Sánchez-Lázaro IJ, Almenar-Bonet L, Martínez-Dolz L, Buendía-Fuentes F, Navarro-Manchón J, Raso-Raso R et al (2010) Preliminary results of a prospective randomized study of cyclosporine versus tacrolimus in the development of cardiac allograft vasculopathy at 1 year after heart transplantation. Transplant Proc 42(8):3199–3200. https://www.sciencedirect.com/science/article/pii/S004113451000713X. (PMID: 2097065010.1016/j.transproceed.2010.05.055)
Schweiger M, Wasler A, Prenner G, Stiegler P, Stadlbauer V, Schwarz M et al (2006) Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Transpl Immunol 16(1):46–51. (PMID: 1670117610.1016/j.trim.2006.02.001)
Segovia J, Rodríguez-Lambert JL, Crespo-Leiro MG, Almenar L, Roig E, Gómez-Sánchez MA et al (2006) A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 81(11):1542–1548. https://journals.lww.com/transplantjournal/Fulltext/2006/06150/A_Randomized_Multicenter_Comparison_of_Basiliximab.8.aspx. (PMID: 1677024310.1097/01.tp.0000209924.00229.e5)
Söderlund C, Rådegran G (2015) Immunosuppressive therapies after heart transplantation — the balance between under- and over-immunosuppression. Transplant Rev 29(3):181–189. https://www.sciencedirect.com/science/article/pii/S0955470X15000099. (PMID: 10.1016/j.trre.2015.02.005)
Starling RC, Hare JM, Hauptman P, McCurry KR, Mayer HW, Kovarik JM et al (2004) Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure–effect modeling. Am J Transplant 4(12):2126–2131. https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1600-6143.2004.00601.x. (PMID: 1557591810.1046/j.1600-6143.2004.00601.x)
Starling RC, Armstrong B, Bridges ND, Eisen H, Givertz MM, Kfoury AG et al (2019) Accelerated allograft vasculopathy with rituximab after cardiac transplantation. J Am Coll Cardiol 74(1):36–51. (PMID: 3127255010.1016/j.jacc.2019.04.056)
Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG et al (2011) Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11(11):2405–2413. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-6143.2011.03757.x. (PMID: 2194293010.1111/j.1600-6143.2011.03757.x)
Stypmann J, Engelen MA, Eckernkemper S, Amler S, Gunia S, Sindermann JR et al (2011) Calcineurin inhibitor-free immunosuppression using everolimus (certican) after heart transplantation: 2 years’ follow-up from the University Hospital Münster. Transplant Proc 43(5):1847–1852. https://www.sciencedirect.com/science/article/pii/S0041134511002740. (PMID: 2169328810.1016/j.transproceed.2010.12.062)
Tarek E-S, Belperio John A, Strieter Robert M, Remick Daniel G, Fairchild Robert L (2005) Inhibition of polymorphonuclear leukocyte–mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation 112(3):320–331. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.104.516708. (PMID: 10.1161/CIRCULATIONAHA.104.516708)
Teuteberg JJ, Shullo MA, Zomak R, Toyoda Y, McNamara DM, Bermudez C et al (2010) Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant 10(2):382–388. (PMID: 1988912610.1111/j.1600-6143.2009.02856.x)
Thibodeau JT, Mishkin JD, Patel PC, Kaiser PA, Ayers CR, Mammen PPA et al (2013) Tolerability of sirolimus: a decade of experience at a single cardiac transplant center. Clin Transpl 27(6):945–952. (PMID: 10.1111/ctr.12269)
Thrush PT, Pahl E, Naftel DC, Pruitt E, Everitt MD, Missler H et al (2016) A multi-institutional evaluation of antibody-mediated rejection utilizing the pediatric heart transplant study database: incidence, therapies and outcomes. J Heart Lung Transplant 35(12):1497–1504. https://www.sciencedirect.com/science/article/pii/S1053249816301929. (PMID: 2743175310.1016/j.healun.2016.06.014)
Tönshoff B (2020) Immunosuppressants in organ transplantation. In: Kiess W, Schwab M, van den Anker J (eds) Pediatric pharmacotherapy. Springer, Cham, pp 441–469. https://doi.org/10.1007/164_2019_331. (PMID: 10.1007/164_2019_331)
Vera M-S, Branislav S, Miodrag P (2017) Modern immunosuppressive agents after heart transplantation. Curr Trends Cardiol 1(2) https://www.alliedacademies.org/abstract/modern-immunosuppressive-agents-after-heart-transplantation-8676.html.
Viganò M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J et al (2007) Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 26(6):584–592. https://www.jhltonline.org/article/S1053-2498(07)00254-9/abstract. (PMID: 1754378110.1016/j.healun.2007.03.005)
Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E et al (2010) Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl Infect Dis 12(1):23–30. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1399-3062.2009.00448.x. (PMID: 1974428410.1111/j.1399-3062.2009.00448.x)
Wang M-H, Milekhin V, Zhang H, Huang H-Z (2003) FTY720, a new immunosuppressant, as rescue therapy in mouse cardiac transplantation. Acta Pharmacol Sin 24(9):847–852. (PMID: 12956930)
Wang SS, Chou NK, Chi NH, Wu IH, Chen YS, Yu HY et al (2008) Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus. Transplant Proc 40(8):2607–2608. https://www.sciencedirect.com/science/article/pii/S0041134508011500. (PMID: 1892981410.1016/j.transproceed.2008.08.072)
Wang S-S, Chou N-K, Chi N-H, Huang S-C, Wu I-H, Wang C-H et al (2010) The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate. Transplant Proc 42(3):938–939. (PMID: 2043020910.1016/j.transproceed.2010.03.002)
Wang W, Yin H, Li X, Hu X, Yang X, Liu H et al (2012) A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin. Chin Med J 125(6):1135–1140. (PMID: 2261354310.1142/S0192415X08006478)
Wang R, Moura LAZ, Lopes SV, da Costa FDA, Souza Filho NFS, Fernandes TL et al (2015) Reduced progression of cardiac allograft vasculopathy with routine use of induction therapy with basiliximab. Arq Bras Cardiol 105(2):176–183. (PMID: 261078154559127)
Whitson BA, Kilic A, Lehman A, Wehr A, Hasan A, Haas G et al (2015) Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents. Clin Transpl 29(1):9–17. (PMID: 10.1111/ctr.12469)
Yan T, Tal H, Eugenia R, Boilson BA, Schirger JA, Pereira NL et al (2012) Sirojlimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation 125(5):708–720. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.040360. (PMID: 10.1161/CIRCULATIONAHA.111.040360)
Ye F, Ying-Bin X, Yu-Guo W, Hetzer R (2009) Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis. In: Database of abstracts of reviews of effects (DARE): quality-assessed reviews. Centre for Reviews and Dissemination (UK). https://www.ncbi.nlm.nih.gov/books/NBK78512/.
Zuckermann A, Keogh A, Crespo-Leiro MG, Mancini D, Vilchez FG, Almenar L et al (2012) Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency. Am J Transplant 12(9):2487–2497. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-6143.2012.04131.x. (PMID: 2277643010.1111/j.1600-6143.2012.04131.x)
Zuckermann A, Eisen H, Tai SS, Li H, Hahn C, Crespo-Leiro MG (2014) Sirolimus conversion after heart transplant: risk factors for acute rejection and predictors of renal function response. Am J Transplant 14(9):2048–2054. https://pennstate.pure.elsevier.com/en/publications/sirolimus-conversion-after-heart-transplant-risk-factors-for-acut. (PMID: 2530703610.1111/ajt.12833)
فهرسة مساهمة: Keywords: Heart transplantation; Immunosuppression
المشرفين على المادة: 0 (Calcineurin Inhibitors)
0 (Immunosuppressive Agents)
0 (Steroids)
تواريخ الأحداث: Date Created: 20220323 Date Completed: 20220708 Latest Revision: 20220708
رمز التحديث: 20221213
DOI: 10.1007/164_2021_569
PMID: 35318509
قاعدة البيانات: MEDLINE
الوصف
تدمد:0171-2004
DOI:10.1007/164_2021_569